JNJ - JNJ COVID-19 vaccine snafu at Emergent plant: FDA clears another batch of doses

Scott Olson/Getty Images News The FDA has greenlighted another set of COVID-19 vaccine doses made for Johnson & Johnson ([[JNJ]] +1.7%) by the contract manufacturer Emergent BioSolutions ([[EBS]] +0.3%) at the company’s Baltimore manufacturing facility, Bloomberg reported. The batch is reportedly enough for 15M doses, and yet to undergo the “fill-finish” process, according to a person familiar with the matter. JNJ and Emergent have not responded for requests for comment. The vaccine plant came under regulatory scrutiny after a manufacturing mix-up made as many as 15M doses useless, prompting the FDA to launch an investigation and weigh on the status of about 100M doses. Later, the federal agency determined that 60M doses manufactured at the plant were to be discarded due to possible contamination. About 10M doses were cleared for distribution. In mid-June, the FDA authorized the distribution of another 14M doses. Amid concerns over safety and manufacturing problems, JNJ faced a steep decline

For further details see:

JNJ COVID-19 vaccine snafu at Emergent plant: FDA clears another batch of doses